Market Place
Sourcing Support
Rhizen Announces Data Presentations at ESMO 2022 for Its Clinical Stage Assets
09 Sep 2022 //
BUSINESSWIRE
Rhizen Pharma Presents Data on Differentiated PARP and DHODH Inhibitor Programs
11 Apr 2022 //
BUSINESSWIRE
Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase I/Ib
01 Nov 2021 //
BUSINESSWIRE
Rhizen Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530)
13 Oct 2021 //
BUSINESSWIRE
Rhizen Begins Dosing in Phase II Study of Tenalisib in Breast Cancer
13 Oct 2021 //
BUSINESSWIRE
Rhizen doses first subject in Phase II Covid-19 oral drug trial in India
22 Sep 2021 //
CLINICALTRIALSARENA
Rhizen Pharmaceuticals Doses 1st Patient in Phase 2 of RP7214 in Covid-19
21 Sep 2021 //
BUSINESSWIRE
First new chemical entity discovered by Indian scientists gets USFDA approval
22 Feb 2021 //
BUSINESSTODAY
Alembic partner’s anti blood cancer drug gets U.S. FDA nod
09 Feb 2021 //
THEHINDU
Rhizen Announces US FDA Acceptance of its IND Application for RP7214
01 Dec 2020 //
BUSINESSWIRE
Alembic arm inks pact with Curon to develop cancer treatment drug Greater China
13 Oct 2020 //
ECONOMIC TIMES
Alembic Pharma share price gains as associate company enters agreement Tenalisib
12 Oct 2020 //
MONEYCONTROL
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.